Status:
COMPLETED
A Study Based on Data From German Registries That Looks at Characteristics of People Who Take the Medicine Empagliflozin for Type 2 Diabetes
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18-80 years
Brief Summary
Description of the real-life treatment of adult patients with type-2 diabetes mellitus (T2DM) receiving Empagliflozin, comparing the characteristics of patients starting Empagliflozin in three time in...
Eligibility Criteria
Inclusion
- At least two outpatient T2DM diagnoses (ICD E11.-) in two different quarters and/or at least one inpatient T2DM diagnosis (ICD E11)
- At least one prescription of an empagliflozin-containing antidiabetic drug: Jardiance® (Empagliflozin, ATC A10BK03, former A10BX12) or Synjardy® (Empagliflozin/ Met¬for¬min, ATC A10BD20)
Exclusion
- Any diagnosis of T1DM
Key Trial Info
Start Date :
September 16 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2019
Estimated Enrollment :
9571 Patients enrolled
Trial Details
Trial ID
NCT04098575
Start Date
September 16 2019
End Date
December 31 2019
Last Update
March 29 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Diabetes Agenda 2010 GmbH
Mahlow, Germany, 15831